[1] |
ESLAM M, GEORGE J. Reply to: Correspondence on "A new definition for metabolic associated fatty liver disease: an international expert consensus statement": MAFLD: Moving from a concept to practice[J]. J Hepatol, 2020, 73(5): 1268-1269. DOI: 10.1016/j.jhep.2020.06.036.
|
[2] |
LEI F, QIN JJ, SONG X, et al. The prevalence of MAFLD and its association with atrial fibrillation in a nationwide health check-up population in China[J]. Front Endocrinol (Lausanne), 2022, 13: 1007171. DOI: 10.3389/fendo.2022.1007171.
|
[3] |
OZTURK K, UYGUN A, GULER AK, et al. Nonalcoholic fatty liver disease is an independent risk factor for atherosclerosis in young adult men[J]. Atherosclerosis, 2015, 240(2): 380-386. DOI: 10.1016/j.atherosclerosis.2015.04.009.
|
[4] |
BENJAMIN EJ, VIRANI SS, CALLAWAY CW, et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association[J]. Circulation, 2018, 137(12): e67-e492. DOI: 10.1161/CIR.0000000000000558.
|
[5] |
LOZANO R, NAGHAVI M, FOREMAN K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010[J]. Lancet, 2012, 380(9859): 2095-2128. DOI: 10.1016/S0140-6736(12)61728-0.
|
[6] |
KOZAKOVA M, PALOMBO C, ENG MP, et al. Fatty liver index, gamma-glutamyltransferase, and early carotid plaques[J]. Hepatology, 2012, 55(5): 1406-1415. DOI: 10.1002/hep.25555.
|
[7] |
JOHRI AM, NAMBI V, NAQVI TZ, et al. Recommendations for the assessment of carotid arterial plaque by ultrasound for the characterization of atherosclerosis and evaluation of cardiovascular risk: from the American Society of Echocardiography[J]. J Am Soc Echocardiogr, 2020, 33(8): 917-933. DOI: 10.1016/j.echo.2020.04.021.
|
[8] |
YU C, WANG M, ZHENG S, et al. Comparing the diagnostic criteria of MAFLD and NAFLD in the Chinese population: a population-based prospective cohort study[J]. J Clin Transl Hepatol, 2022, 10(1): 6-16. DOI: 10.14218/JCTH.2021.00089.
|
[9] |
SAKURAI Y, KUBOTA N, YAMAUCHI T, et al. Role of insulin resistance in MAFLD[J]. Int J Mol Sci, 2021, 22(8): 4156. DOI: 10.3390/ijms22084156.
|
[10] |
DUAN Y, PAN X, LUO J, et al. Association of inflammatory cytokines with non-alcoholic fatty liver disease[J]. Front Immunol, 2022, 13: 880298. DOI: 10.3389/fimmu.2022.880298.
|
[11] |
HUANG X, YAO Y, HOU X, et al. Macrophage SCAP contributes to metaflammation and lean NAFLD by activating STING-NF-κB signaling pathway[J]. Cell Mol Gastroenterol Hepatol, 2022, 14(1): 1-26. DOI: 10.1016/j.jcmgh.2022.03.006.
|
[12] |
WU T, YE J, SHAO C, et al. Varied relationship of lipid and lipoprotein profiles to liver fat content in phenotypes of metabolic associated fatty liver disease[J]. Front Endocrinol (Lausanne), 2021, 12: 691556. DOI: 10.3389/fendo.2021.691556.
|
[13] |
ARROYAVE-OSPINA JC, WU Z, GENG Y, et al. Role of oxidative stress in the pathogenesis of non-alcoholic fatty liver disease: implications for prevention and therapy[J]. Antioxidants (Basel), 2021, 10(2): 174. DOI: 10.3390/antiox10020174.
|
[14] |
HERNANDEZ GV, SMITH VA, MELNYK M, et al. Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH[J]. Am J Physiol Gastrointest Liver Physiol, 2020, 318(3): G582-G609. DOI: 10.1152/ajpgi.00344.2019.
|
[15] |
YANG B, LUO W, WANG M, et al. Macrophage-specific MyD88 deletion and pharmacological inhibition prevents liver damage in non-alcoholic fatty liver disease via reducing inflammatory response[J]. Biochim Biophys Acta Mol Basis Dis, 2022, 1868(10): 166480. DOI: 10.1016/j.bbadis.2022.166480.
|
[16] |
HE Y, HWANG S, CAI Y, et al. MicroRNA-223 ameliorates nonalcoholic steatohepatitis and cancer by targeting multiple inflammatory and oncogenic genes in hepatocytes[J]. Hepatology, 2019, 70(4): 1150-1167. DOI: 10.1002/hep.30645.
|
[17] |
YOU D, QIAO Q, ONO K, et al. miR-223-3p inhibits the progression of atherosclerosis via down-regulating the activation of MEK1/ERK1/2 in macrophages[J]. Aging (Albany NY), 2022, 14(4): 1865-1878. DOI: 10.18632/aging.203908.
|
[18] |
ANSTEE QM, MANTOVANI A, TILG H, et al. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(7): 425-439. DOI: 10.1038/s41575-018-0010-0.
|
[19] |
GUO YC, ZHOU Y, GAO X, et al. Association between nonalcoholic fatty liver disease and carotid artery disease in a community-based Chinese population: a cross-sectional study[J]. Chin Med J (Engl), 2018, 131(19): 2269-2276. DOI: 10.4103/0366-6999.241797.
|
[20] |
SINN DH, GWAK GY, CHO J, et al. Modest alcohol consumption and carotid plaques or carotid artery stenosis in men with non-alcoholic fatty liver disease[J]. Atherosclerosis, 2014, 234(2): 270-275. DOI: 10.1016/j.atherosclerosis.2014.03.001.
|
[21] |
CHEN Z, YANG YG. Guidelines for the diagnosis and treatment of carotid stenosis[J/CD]. Chin J Vasc Surg(Electronic Version), 2017, 9(3): 169-175. DOI:
陈忠, 杨耀国. 颈动脉狭窄诊治指南[J/CD]. 中国血管外科杂志(电子版), 2017, 9(3): 169-175. DOI:
|
[22] |
SINN DH, CHO SJ, GU S, et al. Persistent nonalcoholic fatty liver disease increases risk for carotid atherosclerosis[J]. Gastroenterology, 2016, 151(3): 481-488. e1. DOI: 10.1053/j.gastro.2016.06.001.
|
[23] |
HAACKE C, ALTHAUS A, SPOTTKE A, et al. Long-term outcome after stroke: evaluating health-related quality of life using utility measurements[J]. Stroke, 2006, 37(1): 193-198. DOI: 10.1161/01.STR.0000196990.69412.fb.
|
[24] |
PISTO P, SANTANIEMI M, BLOIGU R, et al. Fatty liver predicts the risk for cardiovascular events in middle-aged population: a population-based cohort study[J]. BMJ Open, 2014, 4(3): e004973. DOI: 10.1136/bmjopen-2014-004973.
|
[25] |
Writing Group Members, LLOYD-JONES D, ADAMS RJ, et al. Heart disease and stroke statistics—2010 update: a report from the American Heart Association[J]. Circulation, 2010, 121(7): e46-e215. DOI: 10.1161/CIRCULATIONAHA.109.192667.
|
[26] |
LAL BK, DUX MC, SIKDAR S, et al. Asymptomatic carotid stenosis is associated with cognitive impairment[J]. J Vasc Surg, 2017, 66(4): 1083-1092. DOI: 10.1016/j.jvs.2017.04.038.
|
[27] |
AMBROSETTI M, PEDRETTI RF. Does metabolic syndrome predict silent carotid stenosis in coronary patients?[J]. Intern Emerg Med, 2008, 3(1): 81-82. DOI: 10.1007/s11739-008-0103-9.
|
[28] |
REN Z, SIMONS P, WESSELIUS A, et al. Relationship between NAFLD and coronary artery disease: A Mendelian randomization study[J]. Hepatology, 2023, 77(1): 230-238. DOI: 10.1002/hep.32534.
|
[1] | Haiqing GUO, Mingliang LI, Feng LIU, Jing ZHANG. Prevalence, influencing factors, and fibrosis risk stratification of metabolic dysfunction-associated fatty liver disease in the health check-up population in Beijing, China[J]. Journal of Clinical Hepatology, 2025, 41(4): 643-649. doi: 10.12449/JCH250408 |
[2] | Decai KONG, Xiaojing ZHANG, Yangguang YUN, Haoyu DUAN, Junfeng YE. Risk factors for biliary stricture and prognosis after orthotopic liver transplantation[J]. Journal of Clinical Hepatology, 2024, 40(11): 2253-2259. doi: 10.12449/JCH241119 |
[3] | Jing KUANG, Shuangqin TENG, Tongtong SHEN, Yiran YAN, Wei WANG, Chuan SHEN, Caiyan ZHAO. Risk factors for portopulmonary hypertension in liver cirrhosis and construction of a predictive model[J]. Journal of Clinical Hepatology, 2024, 40(9): 1802-1806. doi: 10.12449/JCH240914 |
[4] | Linna YUAN, Yihui CHEN, Hengbin NA, Jie LU, Ye LIU, Wu LI. Primary biliary cholangitis with metabolic associated fatty liver disease: Clinical features and risk factors[J]. Journal of Clinical Hepatology, 2024, 40(8): 1598-1604. doi: 10.12449/JCH240815 |
[5] | Yingdie ZHU, Zhijiao ZHANG, Guilin ZHANG, Yunkun GAO, Mengyao ZHENG, Hua HUANG, Gongfang ZHAO. Association of metabolic associated fatty liver disease with carotid atherosclerotic plaque and stenosis[J]. Journal of Clinical Hepatology, 2024, 40(8): 1591-1597. doi: 10.12449/JCH240814 |
[6] | Tianfu LIU, Liang WANG, Lingyi ZHANG. Risk factors for non-neoplastic portal vein thrombosis in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2023, 39(9): 2122-2127. doi: 10.3969/j.issn.1001-5256.2023.09.014 |
[7] | Cheng ZHOU, Ran JIA, Jingjing WEI, Chenlu ZHAO, Dongfang SHANG, Wenxia ZHAO. Risk factors for cognitive impairment associated with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2022, 38(11): 2592-2595. doi: 10.3969/j.issn.1001-5256.2022.11.031 |
[8] | Siqin LIU, Xiaomei WANG, Xia LI, Luwen LIANG, Ke WANG, Rui WANG. Covert hepatic encephalopathy in liver cirrhosis: Risk factors and prognosis[J]. Journal of Clinical Hepatology, 2022, 38(2): 359-364. doi: 10.3969/j.issn.1001-5256.2022.02.020 |
[9] | Yao ChengZi, Liu ZiZhen, Feng Gong, He Na, Mi Man. Risk factors for childhood nonalcoholic fatty liver disease and related prevention and management strategies[J]. Journal of Clinical Hepatology, 2020, 36(7): 1623-1626. doi: 10.3969/j.issn.1001-5256.2020.07.038 |
[10] | Ren DanDan, Liu Na, Zhou LuLu, Zhang Nan, Li ChunXia, Dong Bing, Xu GuangHua. Risk factors for hepatitis B virus-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(7): 1634-1638. doi: 10.3969/j.issn.1001-5256.2020.07.041 |
[11] | Yao ChengZi, Feng Gong, Yu WenSi, Du Huan, Mi Man. Risk factors for the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(2): 433-436. doi: 10.3969/j.issn.1001-5256.2020.02.044 |
[12] | Huang ZhiPeng, Jiang JianJia, Huang ZiCheng, Guo GuiYuan, Zhou APei, Liu XiaoQiang. Risk factors of nonalcoholic fatty liver disease with a normal visceral adipose tissue area[J]. Journal of Clinical Hepatology, 2019, 35(5): 1061-1064. doi: 10.3969/j.issn.1001-5256.2019.05.025 |
[13] | Zhu ZiYi, Liu Yuan, Wang WenBo, Jiang ZhongYong, Chang Kai, Ye YuSheng, Xiong Jie. Mechanism of HCV stimulation of human umbilical vein endothelial cells in the pathogenesis of atherosclerosis[J]. Journal of Clinical Hepatology, 2019, 35(6): 1313-1317. doi: 10.3969/j.issn.1001-5256.2019.06.026 |
[14] | Zhao Jian, Wei Bo, Liang Chun. Association between hepatitis C virus infection and atherosclerosis[J]. Journal of Clinical Hepatology, 2018, 34(2): 407-409. doi: 10.3969/j.issn.1001-5256.2018.02.042 |
[15] | Yu ZhiRui, Wei GuoXi, Liu QiChang, Jin PeiMin. Risk factors for HBV-related liver cirrhosis complicated by acute upper gastrointestinal bleeding[J]. Journal of Clinical Hepatology, 2017, 33(5): 860-863. doi: 10.3969/j.issn.1001-5256.2017.05.013 |
[16] | Zhao HongXin, Yan Rong, Niu ChunYan, Zhou YongLi, Wang Jia, Cao RuiQi. Prevalence and associated risk factors for obesity and nonalcoholic fatty liver disease in adolescents in Xi′an, Shaanxi province, China[J]. Journal of Clinical Hepatology, 2015, 31(8): 1248-1251. doi: 10.3969/j.issn.1001-5256.2015.08.016 |
[17] | Chen BiHua, Zhang Wei, Wu Pei, Huang Ying. Research advances in risk factors for primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(12): 2088-2092. doi: 10.3969/j.issn.1001-5256.2015.12.024 |
[18] | Qu BaoGe, Wang Hui, Su JiLiang, Wang ZhongDong, Wang YaFei, Han XinHai, Liu YuanXun, Jia YiGuo, Pan JinDun, Ren GuangYing. Relationship between alcoholic fatty liver disease and carotid intima-media thickness and influencing factors for carotid intima-media thickness[J]. Journal of Clinical Hepatology, 2015, 31(2): 256-260. doi: 10.3969/j.issn.1001-5256.2015.02.027 |
[19] | Liu HongHong, Fu JunLiang, Fu BaoYun, Zhang Zheng, Xu RuoNan, Luo ShengQiang, Shi Ming, Li YongGang, Wang FuSheng. The pathogenesis and risk factors related to prognosis of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2012, 28(2): 153-155. |
[20] | Zhang YiNing, Du HongWei, Liu YanJun, Wang ChaoXia. The diagnosis and risk factors for evaluation of nonalcoholic fatty liver disease in children and adolescents[J]. Journal of Clinical Hepatology, 2011, 27(7): 690-693. |
1. | 朱英嵽,张志娇,张桂林,高云堃,郑梦瑶,黄华,赵公芳. 代谢相关脂肪性肝病与颈动脉粥样硬化斑块及狭窄的关联分析. 临床肝胆病杂志. 2024(08): 1591-1597 . ![]() | |
2. | 赵冬青,曹文英,彭志强. 颈动脉支架置入术与颈动脉内膜剥脱术治疗症状性颈动脉狭窄的对比研究. 黑龙江医药. 2024(06): 1396-1398 . ![]() |